雷贝拉唑联合莫沙必利治疗反流性食管炎的临床观察

Clinical Observation of Rabeprazole Joint Mosapride will the Treatment of the Reflux esophagitis

目的探讨雷贝拉唑联合莫沙必利治疗反流性食管炎(RE)的近期疗效和安全性。方法将经胃镜证实的反流性食管炎患者110例随机分成治疗组和对照组各55例。治疗组:口服雷贝拉唑10mg,早晚各1次餐前服用,莫沙必利每次5mg,3次/d,餐前半小时服用;对照组:奥美拉唑20mg/d,餐前服用,莫沙必利服用方法同上。两组患者均完成6周治疗,对其临床疗效和安全性进行临床观察。结果两组临床症状缓解总有效率(临床症状改善和胃镜下病变黏膜缓解情况)分别为治疗组94.54%(52/55),对照组76.36%(42/55),治疗组总有效率优于对照组(P<0.05),且不良反应少。结论雷贝拉唑联合莫沙必利治疗反流性食管炎临床症状改善迅速,临床疗效优于奥美拉唑联合莫沙必利治疗反流性食管炎,且安全可靠。

Objective Efficacy and safety of Rabeprazole joint Mosapride treatment of the reflux esophagitis（RE）.Methods By gastroscope confirmed the reflux esophagitis 110 cases were randomly divided into patients 55 treatment group and control group.Treatment group： oral Rabeprazole 10mg evening meal times,Mosapride will take time,three times a day,5mg,half an hour before meal.Control group： Prilosec 20mg/d,before dinner,Mosapride will take a method.Two groups of patients were treated for six weeks to finish,the clinical curative effect and safety of clinical observation.Results Two group total effectiveness（clinical symptoms and clinical symptoms improved under the upper） alleviating mucosal lesions respectively 94.54% treatment group（52/55）,76.36% control group（42/55）,the total effective rate in treatment group than in control group（P0.05）,and the adverse reactions.Conclusion Rabeprazole joint Mosapride treat of the reflux esophagitis clinical symptoms improved rapidly,clinically superior to control group,and safe and reliable.